Cause of Inflammation That Led to STRONG Trial Hold of AVXS-101 ‘Unknown,’ AveXis Says
AveXis, a part of Novartis, is working “diligently” with the U.S. Food and Drug Administration to identify steps necessary to lift the hold on its gene therapy trial in types 2 and 3 spinal muscular atrophy (SMA) patients, but the company does not know what caused the…